The value of prognostic factors in small cell lung cancer: Results from a randomised multicenter study with minimum 5 year follow-up

Lung Cancer

Volumn 39, Issue 3, 2003, Pages 303-313

  Bremnes, Roy M ^a   Sundstrom, Stein ^b   Aasebø, Ulf ^a   Kaasa, Stein ^b   Hatlevoll, Reidulv ^c   Aamdal, Steinar ^c  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Extensive disease; Limited disease; Prognostic factors; SCLC; Survival

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SKIN METASTASIS; TASK PERFORMANCE; THROMBOCYTE COUNT; WEIGHT REDUCTION;

EID: 0037374009     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00508-1     Document Type: Article

References (44)

1. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 50:2000;7-33.
2. Johnson D. Management of small cell lung cancer. Current state of the art. Chest. 116:(Suppl.):1999;525S-530S.
3. Sandler A.B. Current management of small cell lung cancer. Semin. Oncol. 24:1997;463-476.
4. Kelly K. New chemotherapy agents for small cell lung cancer. Chest. 111:(Suppl. 2):2000;156S-162S.
5. Ettinger D.S. Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. Semin. Radiat. Oncol. 9:(Suppl. 1):1999;148-150.
6. Pignon J.P., Arrigada R., Ihde D., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327:1992;1618-1624.
7. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J. Clin. Oncol. 10:1992;890-895.
8. Auperin A., Arrigada R., Pignon J.P., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N. Engl. J. Med. 341:1999;476-484.
9. Hainsworth J.D., Gray J.R., Stroup S.L., et al. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung cancer: comparison of sequential phase II trials using different dose intensities. J. Clin. Oncol. 15:1997;3464-3470.
10. Bremnes R, Sundstrom S, Vilsvik J, Aasebo U, Norwegian Lung Cancer Study Group. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited stage small cell lung cancer. J Clin Oncol 2001; 19: 3532-8.
11. Turrisi A.T., Kim K., Blum R., et al. Twice-daily compared to once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340:1999;265-271.
12. Van de Velde H., Bosquee L., Weynants P., Canon J.L., Rosier J.F., Humblet Y. Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic control and high nervous system relapse. Groupe d'Oncologie-Pneumologie Clinique de l'Universite Catholique de Lovain, Brussels and Liege, Belgium. Ann. Oncol. 10:1999;1051-1057.
13. Brugger W., Fetscher S., Hasse J., et al. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin. Oncol. 25:(Suppl. 2):1998;42-48.
14. Coates A., Porzsolt F., Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur. J. Cancer. 33:1997;1025-1030.
15. Vincent M.D., Ashley S.E., Smith I.E. Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur. J. Cancer Clin. Oncol. 23:1987;1589-1599.
16. Spiegelman D., Maurer H., Ware J.H., et al. Prognostic factors in small cell lung carcinoma of the lung: an analysis of 1521 patients. J. Clin. Oncol. 7:1989;344-354.
17. Østerlind K. LDH or NSE or LDH and NSE as pretreatment prognostic factors in small cell lung cancer? A commentary. Lung Cancer. 30:2000;51-53.
18. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide (EP-regimen) is superior to cyclophosphamide, epirubicin, and vincristine (CEV-regimen) in small cell lung cancer: results from a randomized phase III trial with 5 years follow-up. J Clin Oncol 2002;20:4665-72.
19. The World Health Organization. Histological typing of lung tumors. 2nd edition, Geneva, Switzerland: WHO, 1981.
20. Kaplan E.I., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assos. 53:1958;457-481.
21. Cox D.R. Regression models and life tables. J. R. Stat. Soc. B. 34:1972;187-202.
22. Cohen M.H., Makuch R., Johnston-Early A., et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat. Rep. 65:1981;187-195.
23. Souhami R.L., Bradbury I., Geddes D.M., et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 45:1985;2878-2882.
24. Cerny T., Blair V., Anderson H., et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int. J. Cancer. 15:1987;146-149.
25. Østerlind K., Anderson P.K. Prognostic factors in small cell lung cancer: multivariate model based on 728 patients with chemotherapy with or without radiation. Cancer Res. 46:1986;4189-4194.
26. Maestu I., Pastor M., Gomez-Codina J., et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann. Oncol. 8:1997;547-553.
27. Kawahara M., Fukuoka M., Saijo N., et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn. J. Clin. Oncol. 27:1997;158-165.
28. Tamura M., Ueoka H., Kiura K., et al. Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group trials. Acta Med. Okayama. 52:1998;105-111.
29. Paesmans M., Sculier J.P., Lecomte J., et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 89:2000;523-533.
30. Yip D., Harper P.G. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 28:2000;173-185.
31. Rawson N.S.B., Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br. J. Cancer. 61:1990;597-604.
32. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patients Southwest Oncology Group database. J. Clin. Oncol. 8:1990;1563-1574.
33. Wolf M., Holle R., Hans K., Drings P., Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br. J. Cancer. 63:1991;986-992.
34. Maurer L.H., Pajak T.F. Prognostic factors in small cell carcinoma of the lung: a Cancer and Leukemia Group B study. Cancer Treat. Rep. 65:1981;767-774.
35. Sagman U., Maki E., Evans W.K., et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J. Clin. Oncol. 9:1991;1639-1649.
36. Allan S.G., Stewart M.G., Love S., Cornbleet M.A., Smyth J.F., Leonard C.F. Prognosis at presentation of small cell carcinoma of the lung. Eur. J. Cancer. 26:1990;703-705.
37. Quoix E., Purohit A., Faller-Beau M., Moreau L., Oster J.P., Pauli G. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 30:2000;127-134.
38. Edmonson J.H., Kagakos S.W., Selawry O.S., et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell lung carcinoma and adenocarcinoma of the lung. Cancer Treat. Rep. 60:1976;925-932.
39. Cohen M.H., Ihde D.C., Bunn P.A., et al. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat. Rep. 63:1979;163-170.
40. Sheehan R.G., Balaban E.P., Cox J.V., Frenkel E.P. The relative value of conventional staging procedures for developing prognostic models in extensive-stage small-cell lung cancer. J. Clin. Oncol. 8:1990;2047-2053.
41. Jørgensen L.G.M., Østerlind K., Genolla J., et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br. J. Cancer. 74:1996;463-467.
42. Harding M., McAllister J., Hulks G., et al. Neuron specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance. Br. J. Cancer. 61:1990;605-607.
43. Sagman U., Evans W.K., Warr D., et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J. Clin. Oncol. 9:1991;954-961.
44. Stokkel M.P., van Eck-Smit B.L., Zwinderman A.H., Willems L.N., Pauwels E.K. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J. Cancer Res. Clin. Oncol. 124:1998;215-219.